2. Academic Validation
  3. Antiviral activity of K22 against members of the order Nidovirales

Antiviral activity of K22 against members of the order Nidovirales

  • Virus Res. 2018 Feb 15:246:28-34. doi: 10.1016/j.virusres.2018.01.002.
Julie Christiane Françoise Rappe 1,  Adriaan de Wilde 2,  Han Di 3,  Christin Müller 4,  Hanspeter Stalder 5,  Philip V'kovski 6,  Eric Snijder 7,  Margo A Brinton 8,  John Ziebuhr 9,  Nicolas Ruggli 10,  Volker Thiel 11
Affiliations

Affiliations

  • 1 Institute for Virology and Immunology IVI, Mittelhäusern and Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, Switzerland; Department of Infectious Diseases and Pathobiology, University of Bern, Switzerland. Electronic address: [email protected].
  • 2 Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: [email protected].
  • 3 Department of Biology, 623 Petit Science Center, Georgia State University, 161 Jesse Hill Jr Drive, Atlanta, GA 30303, United States. Electronic address: [email protected].
  • 4 Institute of Medical Virology, Justus Liebig University, Giessen, Germany. Electronic address: [email protected].
  • 5 Institute for Virology and Immunology IVI, Mittelhäusern and Bern, Switzerland; Department of Infectious Diseases and Pathobiology, University of Bern, Switzerland. Electronic address: [email protected].
  • 6 Institute for Virology and Immunology IVI, Mittelhäusern and Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, Switzerland; Department of Infectious Diseases and Pathobiology, University of Bern, Switzerland. Electronic address: [email protected].
  • 7 Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: [email protected].
  • 8 Department of Biology, 623 Petit Science Center, Georgia State University, 161 Jesse Hill Jr Drive, Atlanta, GA 30303, United States. Electronic address: [email protected].
  • 9 Institute of Medical Virology, Justus Liebig University, Giessen, Germany. Electronic address: [email protected].
  • 10 Institute for Virology and Immunology IVI, Mittelhäusern and Bern, Switzerland; Department of Infectious Diseases and Pathobiology, University of Bern, Switzerland. Electronic address: [email protected].
  • 11 Institute for Virology and Immunology IVI, Mittelhäusern and Bern, Switzerland; Department of Infectious Diseases and Pathobiology, University of Bern, Switzerland. Electronic address: [email protected].
PMID: 29337162 DOI: 10.1016/j.virusres.2018.01.002
Abstract

Recently, a novel Antiviral compound (K22) that inhibits replication of a broad range of animal and human coronaviruses was reported to interfere with viral RNA synthesis by impairing double-membrane vesicle (DMV) formation (Lundin et al., 2014). Here we assessed potential Antiviral activities of K22 against a range of viruses representing two (sub)families of the order Nidovirales, the Arteriviridae (porcine reproductive and respiratory syndrome virus [PRRSV], equine arteritis virus [EAV] and simian hemorrhagic fever virus [SHFV]), and the Torovirinae (equine torovirus [EToV] and White Bream virus [WBV]). Possible effects of K22 on nidovirus replication were studied in suitable cell lines. K22 concentrations significantly decreasing infectious titres of the viruses included in this study ranged from 25 to 50 μM. Reduction of double-stranded RNA intermediates of viral replication in nidovirus-infected cells treated with K22 confirmed the anti-viral potential of K22. Collectively, the data show that K22 has Antiviral activity against diverse lineages of nidoviruses, suggesting that the inhibitor targets a critical and conserved step during nidovirus replication.

Keywords

Antiviral drug; Double membrane vesicles; K22; Nidoviruses; Replication organelles.

Figures
Products